6Pieber TR, Eugene-Jolchine I, Derobert E, et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with Type Ⅰ diabetes[J]. Diabetes Care,2000,23(2): 157-162.
8Gerich JE. Insulin glargine: long-acting basal insulin analong for improved metabolic control[J]. Curt Med Res Opin,2004,20(1):31-37.
9Luzio SD,Beak P,Owens DR. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with type 2 diabetes[J]. Horm Metab Res, 2003,35(7) :434-438.
4Ebeling P, Jansson P A, Smith U, et al. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin[J]. Diabetes Care, 1997,20 : 1287-1289.
5Rosskamp R H, Park G. Long-acting insulin analogs[J].Diabetes Care,1999, 22(Suppl 2) :B109-B113.
6Vajo Z, Fawcett J, Duckworth W C. Recombinant DNA technology in the treatment of diabetes [ J]. Endocr Rev, 2001,22:706-717.
7McKeage K, Goa K L. Insulin Glargine [ J ]. Drugs, 2001,61 :1599-1624.
8Heinemann L, Linkeschova R, Rave K. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo[J]. Diabetes Care, 2000,23 : 644-649.
9Talaulicar M, Willms B, Rosskamp R. HOE901, ein neues insulin analog zur substitution des basalen insulin-bedarfs bei type 1 diabetes[ J ]. Diabetes Stoffwechsel, 1996,5 : 3-6.
10Ratner R E, Hirsch I B, Neifing J L. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes[J]. Diabetes Care ,2000,23 : 639-643.
7Wang F,Carabine JM,Vergara CM.Insulin glargine:a systematic review of a long-acting insulin analogue[J].Clin Ther,2003,25(6):1541-1577.
8Bode BW,Steed RD,Schleusener DS,et al.Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro:a randomized open-label study using a continuous glucose monitoring system[J].Endocr Pract.2005,11(3):157-164.
9Stratton IM,Adler AI.Neil HA.et al. Association of gly-caemia with macrovascular and microvascular complica-tions of type 2 diabetes(UKPDS 35) :prospective observa-tional study[J]. BMJ,2000,321(7258) :405-412.
10Himch IB. Glycemic variability:it's not just about HbAlcCanymore[ J]. Diabetes Technol Ther, 2005 ,7 (5): 780-783.
